Cargando…

Regional tau deposition measured by [(18)F]THK5317 positron emission tomography is associated to cognition via glucose metabolism in Alzheimer’s disease

BACKGROUND: The recent development of tau-specific positron emission tomography (PET) tracers has allowed in vivo quantification of regional tau deposition and offers the opportunity to monitor the progression of tau pathology along with cognitive impairment. In this study, we investigated the relat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Saint-Aubert, Laure, Almkvist, Ove, Chiotis, Konstantinos, Almeida, Rita, Wall, Anders, Nordberg, Agneta
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2016
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5041516/ https://www.ncbi.nlm.nih.gov/pubmed/27683159 http://dx.doi.org/10.1186/s13195-016-0204-z

Ejemplares similares

Imaging in-vivo tau pathology in Alzheimer’s disease with THK5317 PET in a multimodal paradigm
por: Chiotis, Konstantinos, et al.
Publicado: (2016)

[(18)F]THK5317 imaging as a tool for predicting prospective cognitive decline in Alzheimer’s disease
por: Chiotis, Konstantinos, et al.
Publicado: (2020)

Optimal timing of tau pathology imaging and automatic extraction of a reference region using dynamic [(18)F]THK5317 PET
por: Jonasson, My, et al.
Publicado: (2019)

Assessment of Tau Pathology as Measured by (18)F-THK5317 and (18)F-Flortaucipir PET and Their Relation to Brain Atrophy and Cognition in Alzheimer’s Disease
por: Colato, Elisa, et al.
Publicado: (2021)

Cortical laminar tau deposits and activated astrocytes in Alzheimer’s disease visualised by (3)H-THK5117 and (3)H-deprenyl autoradiography
por: Lemoine, Laetitia, et al.
Publicado: (2017)

Visualization of regional tau deposits using (3)H-THK5117 in Alzheimer brain tissue
por: Lemoine, Laetitia, et al.
Publicado: (2015)

In vivo imaging of tau deposition in Alzheimer’s disease using both [(18)F]-THK5317 and [(18)F]-S16: A pilot human study
por: Fu, Liping, et al.
Publicado: (2022)

Dual tracer tau PET imaging reveals different molecular targets for (11)C-THK5351 and (11)C-PBB3 in the Alzheimer brain
por: Chiotis, Konstantinos, et al.
Publicado: (2018)

Tau positron emission tomography imaging in tauopathies: The added hurdle of off-target binding
por: Lemoine, Laetitia, et al.
Publicado: (2018)

Tau PET imaging in neurodegenerative tauopathies—still a challenge
por: Leuzy, Antoine, et al.
Publicado: (2019)

Tau PET imaging: present and future directions
por: Saint-Aubert, Laure, et al.
Publicado: (2017)

Diverging longitudinal changes in astrocytosis and amyloid PET in autosomal dominant Alzheimer’s disease
por: Rodriguez-Vieitez, Elena, et al.
Publicado: (2016)

Early astrocytosis in autosomal dominant Alzheimer’s disease measured in vivo by multi-tracer positron emission tomography
por: Schöll, Michael, et al.
Publicado: (2015)

Clinical validity of increased cortical binding of tau ligands of the THK family and PBB3 on PET as biomarkers for Alzheimer’s disease in the context of a structured 5-phase development framework
por: Chiotis, Konstantinos, et al.
Publicado: (2021)

Longitudinal Assessment of Tau Pathology in Patients with Alzheimer’s Disease Using [(18)F]THK-5117 Positron Emission Tomography
por: Ishiki, Aiko, et al.
Publicado: (2015)

(18)F-THK5351 Positron Emission Tomography Imaging in Neurodegenerative Tauopathies
por: Ezura, Michinori, et al.
Publicado: (2021)

Analysis of amyloid and tau deposition in Alzheimer's disease using (11)C-Pittsburgh compound B and (18)F-THK 5351 positron emission tomography imaging
por: Chanisa, Chotipanich, et al.
Publicado: (2020)

Longitudinal tau and metabolic PET imaging in relation to novel CSF tau measures in Alzheimer’s disease
por: Leuzy, Antoine, et al.
Publicado: (2019)

Positron emission tomography imaging and clinical progression in relation to molecular pathology in the first Pittsburgh Compound B positron emission tomography patient with Alzheimer’s disease
por: Kadir, Ahmadul, et al.
Publicado: (2011)

Comparative binding properties of the tau PET tracers THK5117, THK5351, PBB3, and T807 in postmortem Alzheimer brains
por: Lemoine, Laetitia, et al.
Publicado: (2017)

Visualization of ischemic stroke-related changes on (18)F-THK-5351 positron emission tomography
por: Huang, Kuo-Lun, et al.
Publicado: (2018)

Alzheimer’s disease profiled by fluid and imaging markers: tau PET best predicts cognitive decline
por: Bucci, Marco, et al.
Publicado: (2021)

A biomarker-validated time scale in years of disease progression has identified early- and late-onset subgroups in sporadic Alzheimer’s disease
por: Almkvist, Ove, et al.
Publicado: (2023)

Assessing THK523 selectivity for tau deposits in Alzheimer’s disease and non–Alzheimer’s disease tauopathies
por: Fodero-Tavoletti, Michelle T, et al.
Publicado: (2014)

(11)C-Pittsburgh compound B and (18)F-THK 5351 positron emission tomography brain imaging in cognitively normal individuals
por: Chotipanich, Chanisa, et al.
Publicado: (2020)

Reduced penetrance of the PSEN1 H163Y autosomal dominant Alzheimer mutation: a 22-year follow-up study
por: Thordardottir, Steinunn, et al.
Publicado: (2018)

Combination of automated brain volumetry on MRI and quantitative tau deposition on THK-5351 PET to support diagnosis of Alzheimer’s disease
por: Kim, Minjae, et al.
Publicado: (2021)

Cross-interaction of tau PET tracers with monoamine oxidase B: evidence from in silico modelling and in vivo imaging
por: Murugan, N. Arul, et al.
Publicado: (2019)

The hippocampal sparing subtype of Alzheimer’s disease assessed in neuropathology and in vivo tau positron emission tomography: a systematic review
por: Ferreira, Daniel, et al.
Publicado: (2022)

Temporal and spatial changes in reactive astrogliosis examined by (18)F-THK5351 positron emission tomography in a patient with severe traumatic brain injury
por: Hatakeyama, Tetsuhiro, et al.
Publicado: (2021)

Comparison of (18)F-T807 and (18)F-THK5117 PET in a Mouse Model of Tau Pathology
por: Brendel, Matthias, et al.
Publicado: (2018)

Association of Phosphorylated Tau Biomarkers With Amyloid Positron Emission Tomography vs Tau Positron Emission Tomography
por: Therriault, Joseph, et al.
Publicado: (2022)

Perfusion-Phase [(18)F]THK5351 Tau-PET Imaging as a Surrogate Marker for Neurodegeneration
por: Brendel, Matthias, et al.
Publicado: (2017)

Optimization and Biodistribution of [(11)C]-TKF, An Analog of Tau Protein Imaging Agent [(18)F]-THK523
por: Kong, Yanyan, et al.
Publicado: (2016)

Relationship between the temporal course of astrogliosis and symptom improvement in cerebral infarction: report of a case monitored using (18)F-THK5351 positron emission tomography
por: Ishibashi, Kenji, et al.
Publicado: (2020)

Spatial Normalization of (18)F-Flutemetamol PET Images Using an Adaptive Principal-Component Template
por: Lilja, Johan, et al.
Publicado: (2019)

Longitudinal pathways of cerebrospinal fluid and positron emission tomography biomarkers of amyloid-β positivity
por: Sala, Arianna, et al.
Publicado: (2020)

CSF Cholinergic Index, a New Biomeasure of Treatment Effect in Patients With Alzheimer’s Disease
por: Karami, Azadeh, et al.
Publicado: (2019)

Cortical microstructural correlates of astrocytosis in autosomal-dominant Alzheimer disease
por: Vilaplana, Eduard, et al.
Publicado: (2020)

Misery Perfusion and Tau Deposition in Atherosclerotic Major Cerebral Artery Disease: A (18)F-Florzolotau Positron Emission Tomography Study
por: Yamauchi, Hiroshi, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_5jbnvn9j740dfqff05o51ip7ur